CDMO BioSpring To Build New API Manufacturing Facility In Germany

Offenbach am Main, Germany - Groundbreaking for the future: Together with Hesse’s Minister President Boris Rhein (CDU) and the Mayor of Offenbach, Dr. Felix Schwenke (SPD), BioSpring today inaugurated a new chapter in its company history on the Offenbach Innovation Campus. The company is building a new production facility that will set new standards and, once completed, become one of the world’s largest production sites for DNA- and RNA-based active pharmaceutical ingredients (APIs). This positions BioSpring as a key economic driver in Hesse and in one of the fastest-growing segments of the biotech industry. 

Minister President Boris Rhein praises BioSpring’s expansion: “BioSpring exemplifies the qualities that define Hesse as a hub for business and technology: world-class research, highly skilled jobs, and investments that drive long-term value creation. Expansions of this kind are essential to enhancing competitiveness and reinforcing Hesse’s leading position in the field of biotechnology. The fact that BioSpring, one of the global leaders in its industry, is headquartered in Hesse is a major asset for the region,” said Minister President Boris Rhein.

Felix Schwenke, Mayor of Offenbach: “BioSpring is not relocating from one city to another. BioSpring is creating entirely new jobs here. That’s not just good news for Offenbach but for the entire region. For the people of Offenbach, it's particularly positive that BioSpring and the city agreed to make this growth happen right here on the Innovation Campus. For the first time, Offenbach will become a serious hub for globally significant biotechnology. Given that biotech is relatively crisis-resilient, this is a major building block in strengthening Offenbach as an economic location and making it future-ready.” 

Dr. Sylvia Wojczewski, CEO of BioSpring: “With our investment in Offenbach, we are setting new standards in nucleic acid drug substance manufacturing,” explained Wojczewski. “In the future, we’ll be able to produce nucleic acids for therapeutic applications on a ton scale. This allows us to support our clients’ growth by offering new high-volume capacity. The investment underscores our position as a global leading industrial manufacturer of synthetic nucleic acids.” 

The new building complex will include three interconnected structures: a manufacturing and warehouse facility, an office area for quality control and production teams, and a glass atrium designed for events. An external solvent tank farm will also be built. Production will be conducted under GMP (Good Manufacturing Practice) conditions, a quality standard that ensures the highest levels of product quality, purity, and safety. In total, the complex will offer over 15,200 m² (approx. 164,000 ft²) of gross floor area and will employ around 200 people. In the long term, BioSpring aims to create additional jobs at the Innovation Campus in Offenbach. The investment amounts to several hundred million euros, with completion planned for the end of 2027. 

“The city of Offenbach has supported our project from day one, from every level of staff up to the mayor himself. Even in challenging moments, everyone has been focused on finding solutions. We feel reassured in our decision to choose Offenbach,” said Wojczewski, also commending the regional government office in Darmstadt for their professional collaboration. 

With nearly three decades of experience, BioSpring is a leading company and commercial provider specializing in the manufacturing and analysis of therapeutic nucleic acids, particularly oligonucleotides, from small preclinical quantities to full-scale commercial production. These short, synthetically produced RNA sequences hold the potential for groundbreaking new therapies, including treatments for cancer and Alzheimer’s disease. They also offer entirely new therapeutic possibilities for the treatment of rare genetic disorders—potentially enabling the complete cure of diseases that were previously considered incurable. 

With the investments now underway in Offenbach, BioSpring will further strengthen its global leadership in the production and analysis of synthetic nucleic acids.